Who are Topas Therapeutics's investors?

Topas Therapeutics's investors include EMBL Ventures, Gimv, Boehringer Ingelheim Venture Fund, BioMedPartners, Epidarex Capital.

Topas Therapeutics

Founded 2016 · 22 employees on LinkedIn · 5 known investors

Find your way into Topas Therapeutics

Paths you didn't know you had: your email and LinkedIn already hold routes to the Topas Therapeutics team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Topas Therapeutics develops nanoparticle-based therapies to induce immune tolerance for autoimmune and immune-mediated diseases. Its lead candidate, TPM502, targets liver sinusoidal endothelial cells and is being developed for celiac disease, having completed a Phase 2a study.

Biotech Healthtech

Founders & leadership

Hugo Fry Chief Executive OfficerHe has 30 years of experience in pharmaceutical and biotech executive roles across multinational corporations, startups, and companies operating in the UK, USA, France, Russia, and Germany, with expertise spanning R&D, industrial affairs, commercial launches, fundraising, licensing, and partnerships.

Christian SchröterChief Operating Officer

Cristina de MinChief Medical Officer

Anne BurgerChief Financial Officer

Alex Marshall Chief Business OfficerAlex Marshall is Chief Business Officer at Topas Therapeutics, where the company develops nanoparticle-based therapies for autoimmune diseases. He brings over 20 years of experience in biopharma business development and strategy from prior roles at RQ Biotechnology, Oxford Biomedica, GE Healthcare, and Oxford University Innovation, and holds a PhD in Biotechnology from Cambridge and an MBA from Warwick.

Investors · 5

EMBL Ventures✓ confirmed by Topas TherapeuticsHeidelberg · $108K – $5.4M

How we know: EMBL Ventures's portfolio page · the company's own site · open dataset · 5k.vc investor directory · Not right? Tell us

Gimv✓ confirmed by Topas TherapeuticsAntwerp · $20M – $400M

How we know: the company's own site · Gimv's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

Boehringer Ingelheim Venture Fund✓ confirmed by Topas TherapeuticsIngelheim am Rhein · $16.2M

How we know: the company's own site · open dataset · 5k.vc investor directory · Not right? Tell us

BioMedPartnerslisted by BioMedPartnersBasel · $648K – $6.5M

How we know: BioMedPartners's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Epidarex Capitallisted by Epidarex CapitalBethesda · $2.5M – $6.3M

How we know: Epidarex Capital's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

Founder mafia

2 people who came through Topas Therapeutics went on to found or lead other companies.

Michael WackerBoard DirectorFounded LimmaTech Biologics Paul SekhriChair of the Board of Supervisory DirectorsFounded Vtvtherapeutics

Related companies · 3

Topaz TxTopaz Therapeutics is developing a platform of next-generation oncology drugs.

Aptose Biosciences Inc.Aptose Biosciences is a biopharmaceutical company developing novel cancer therapeutics, with a focus on acute myeloid leukemia treatments. The company is advancing tuspetinib through clinical trials for AML indications.

Topo TherapeuticsTopo Therapeutics is a drug discovery company developing treatments targeting ion channels and transmembrane proteins for conditions such as pain, epilepsy, and CNS, pulmonary, and renal diseases. It is built around scientific advisors and leadership with expertise in ion channel biology and biophysics.

Companies working in the same space as Topas Therapeutics.

Frequently asked questions

What does Topas Therapeutics do?: Topas Therapeutics develops nanoparticle-based therapies to induce immune tolerance for autoimmune and immune-mediated diseases. Its lead candidate, TPM502, targets liver sinusoidal endothelial cells and is being developed for celiac disease, having completed a Phase 2a study.
Who are Topas Therapeutics's investors?: Topas Therapeutics's investors include EMBL Ventures, Gimv, Boehringer Ingelheim Venture Fund, BioMedPartners, Epidarex Capital.